Abstract
Hepatits C virus is an enveloped virion containing a single-stranded positive sense RNA genome of approximately 9,500 nucleotides. HCV has six major genotypes (1–6) and numerous subtypes. HCV treatment is evolving rapidly.1 Since 1 July 2016, two direct acting-antivirals (DAAs) HARVONI and VIEKIRA PAK have been funded in New Zealand. Both have cure rates of 90+ per cent, fewer side effects and shorter treatment duration than previous treatments. Only patients with virus genotype 1 or those with severe liver disease can currently access these treatments.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
